New Age Alpha Advisors LLC Decreases Position in DexCom, Inc. $DXCM

New Age Alpha Advisors LLC lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 26.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 81,185 shares of the medical device company’s stock after selling 28,543 shares during the quarter. New Age Alpha Advisors LLC’s holdings in DexCom were worth $5,388,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. CVA Family Office LLC raised its position in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. ORG Partners LLC increased its position in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 281 shares during the period. Spire Wealth Management increased its position in shares of DexCom by 113.8% in the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after acquiring an additional 305 shares during the period. Aventura Private Wealth LLC purchased a new position in shares of DexCom in the fourth quarter valued at about $43,000. Finally, Rothschild Investment LLC increased its position in shares of DexCom by 59.9% in the third quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 245 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity

In related news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total transaction of $60,730.12. Following the sale, the director owned 25,007 shares of the company’s stock, valued at $1,500,670.07. The trade was a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $59.91, for a total transaction of $101,847.00. Following the sale, the executive vice president directly owned 109,504 shares in the company, valued at $6,560,384.64. The trade was a 1.53% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,112 shares of company stock worth $379,990 in the last three months. 0.28% of the stock is currently owned by insiders.

DexCom Stock Performance

Shares of DXCM opened at $72.10 on Monday. The firm’s 50-day moving average price is $63.58 and its 200-day moving average price is $66.02. The firm has a market capitalization of $27.82 billion, a price-to-earnings ratio of 30.81, a PEG ratio of 1.19 and a beta of 1.40. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $89.98.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.32 EPS. Sell-side analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on DXCM shares. Truist Financial restated a “buy” rating and issued a $80.00 price objective (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Weiss Ratings upgraded shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. Bank of America decreased their price objective on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Canaccord Genuity Group set a $82.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Monday, May 18th. Finally, Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $82.21.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.